

ABSTRACTVACCINE

5        Effective stimulation of immune responses is achieved through the use of a  
group A streptococcal antigen combined with proteosome adjuvant. The  
compositions are provided in particular for intranasal administration. The vaccine  
compositions are provided for use in inducing an immune response in an individual  
for the treatment or prophylaxis of group A streptococcal infection in an individual,  
10 preferably via prevention or reduction of colonisation of the throat following  
intranasal administration.